Compare DSWL & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | HOWL |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 64.5M |
| IPO Year | 1995 | 2021 |
| Metric | DSWL | HOWL |
|---|---|---|
| Price | $3.46 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 13.1K | ★ 891.1K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | ★ 5.83% | N/A |
| EPS Growth | ★ 20.23 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $65,664,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.93 | $0.56 |
| 52 Week High | $4.48 | $2.38 |
| Indicator | DSWL | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 33.26 |
| Support Level | $3.28 | $0.62 |
| Resistance Level | $3.49 | $0.67 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 51.09 | 30.93 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.